PEPGEN INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PEPGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $7.00K.
- PEPGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $27.00K, a 93.37% decline year-over-year.
- PEPGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $407.00K.
- PEPGEN INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $1.40M, a 1550.59% increase year-over-year.
- PEPGEN INC. stock issued during period, value, stock options exercised for fiscal 2025 was $67.00K, a 97.00% decline from fiscal 2024.
- PEPGEN INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.23M, a 946.95% increase from fiscal 2023.
- PEPGEN INC. stock issued during period, value, stock options exercised for fiscal 2023 was $213.00K, a 1.84% decline from fiscal 2022.
- PEPGEN INC. stock issued during period, value, stock options exercised for fiscal 2022 was $217.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $7.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $67.00K 10-K · filed 2026-03-04 | |
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-12 | |
| 2024-12-31 | $2.23M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $407.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.40M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $395.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $213.00K 10-K · filed 2025-02-24 | |
| 2023-06-30 | $85.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $130.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $217.00K 10-K/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |